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Forest, Va.; Ginny Daniels, fourth-year pharmacy student from Dover, Ohio; Kelsey Fink, fifth-year pharmacy student from
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Introduction
As the world's leading cause of death, cardiovascular disease
(CVD) is a fairly common diagnosis in patients, although it
can manifest in different ways. There are many factors that
contribute to CVD, including poor diet, lack of exercise, hypertension and dyslipidemia. In a select number of patients,
poor cardiovascular outcomes can be attributed to genetic
ACPE Universal Activity Number (UA.t~: 0048-0000-14-031-HO 1-P mutations. Homozygous familial hypercholesterolemia, also
'-------------------------~ known as type II hyperlipoproteinemia, most frequently results from mutations in both alleles coding for LDL receptors.
This mutation of the LDL receptors greatly reduces the
Objectives
After completion of this program, the reader should be able amount of serum cholesterol absorbed by cells.1 There are
several mechanisms by which this occurs, including inability
to:
1. Describe the clinical symptoms of homozygous familof the receptor to be transported to the cell surface, bind to
ial hypercholesterolemia (HoFH).
LDL when at the surface or be internalized or released upon
binding the LDL cholesteroJ.2 It is estimated that HoFH af2. Identify conventional and adjunct treatments used for
HoFH before the development and FDA approval of fects approximately one in 1 million individuals,3,4 although
it is likely that this disease is grossly under diagnosed, given
mipomersen and lomitapide.
3. Identify the mechanism of action for both mipomersen
the number of diagnosed cases of CVD and the number of
attributable factors. 4 Without proper lipid-lowering treatand lomitapide.
4. Identify mipomersen and lomitapide's place in
ment, life expectancy is drastically reduced to before age 204
therapy in the treatment of HoFH.
or the early 20s3, with a 100 percent mortality rate by age
30.5 The purpose of this paper is to review HoFH and to de5. Discuss the common adverse events and appropriate
monitoring parameters associated with mipomersen
scribe two emerging pharmacological treatment options.
and lomitapide therapy.
Overview of Homozygous Familial Hypercholesterolemia
Homozygous familial hypercholesterolemia presents with
Abstract
Homozygous familial hypercholesterolemia (HoFH) is a rare several characteristic symptoms early in life: total serum
disease that involves mutations in the genes coding for low cholesterol of greater than 600mg/dL 1 (up to 1,200mg/dL5),
density lipoprotein (LDL) receptors, preventing the uptake of coronary artery disease, xanthomas (a yellow-orange, lipidLDL cholesterol from the serum and resulting in extremely filled nodule) on the skin during childhood, 1.5 angina of effort
high cholesterol levels.1 Between December 2012, and Janu- (suffocating chest pain occurring during physical exertion),3,5
ary 2013, two orphan drugs were approved by the U.S. Food aortic stenosis and myocardial infarction (Ml).5 In some paand Drug Administration (FDA) for the treatment of HoFH. tients, an Ml is known to occur as young as 2 years old.3 InMipomersen (Kynamro®) is a subcutaneous injection that terestingly, diabetes, hypertension and obesity are not often
functions as an antisense oligonucleotide inhibitor and ulti- seen in patients with HoFH.5 Patients who are most likely to
mately prevents the translation of mRNA coding for apolipo- develop HoFH are those who have parents that are ·diagprotein B (apoB)-100 which binds to LDL and very low den- nosed with or have a positive family history of heterozygous
sity lipoprotein (vLDL) cholesterol.7 Lomitapide (Juxtapid®) familial hypercholesterolemia. Clinically, it may be difficult to
is an oral drug that inhibits microsomal triglyceride protein distinguish between severe heterozygous and normal(MTP), an enteric and hepatic protein that promotes the lipid presenting HoFH; in homozygous familial hypercholestransfer to apoB and allows a complex to form. Through the teroiemia, the patient's fibroblasts or lymphocytes will show
inhibition ofMTP, vLDL cholesterol and chylomicrons are not a reduction of LDL receptor activity of 20 percent or more.1
formed. Each of these drugs, when combined with a low-fat Genetic testing will also provide a conclusive diagnosis and is
diet and additional lipid-lowering therapy, which may in- useful in identifying silent cases, giving health care profesclude statins, resins and LDL-apheresis, can produce a clini- sionals a better understanding of the disease's clinical
cally significant reduction in serum LDL cholesterol.7,14 Be- presentation and prognosis, as well as providing earlier diagfore the approval of these two drugs, patients faced a greatly noses of familial hypercholesterolemia.z
shortened lifespan, uncertain and nonspecific treatment options and serious complications secondary to HoFH.1,3-5
Because HoFH is so rare, the best way to treat it has been
with conventional methods used in treating "normal" or
commonly occurring hyperlipidemia. Lifestyle changes, such
This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.
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as eating a diet low in fat and cholesterol, increasing exercise,
weight control, moderating alcohol intake and smoking cessation are often encouraged. There are several conventional
drug options available to help treat the symptoms of HoFH.
Statins and resins (such as cholestyramine; also known as
bile acid sequestrants) can help to reduce serum levels of
LDL cholesterol by increasing the activity of the LDL receptors; however, these drugs will not be effective in removing
LDL cholesterol from the blood if the LDL receptor is absent
or nonfunctionaJ.1 Bile acid resins can also cause undesirable
gastrointestinal (GI) side effects and can deplete fat-soluble
vitamins (vitamins A, D, E and K).3 Fibrates, nicotinic acid
(also known as niacin, a B vitamin that has shown to improve
the overall lipid profile) and cholesterol absorption inhibitors like ezetimibe have also been used to improve the levels
of serum LDL. The most promising nonpharmacological
treatment for HoFH is LDL-apheresis. Somewhat similar to
dialysis, this procedure works by passing the patient's blood
through adsorption columns to remove LDL cholesterol and
then returning the blood back to the patient. The components of the columns and the process itself may vary, but the
goal is to remove as much LDL cholesterol as possible.3
Treatment regimens that include a statin tend to prolong the
effects of LDL-apheresis and slow the rebound rate of LDL
cholesteroJ.1 Although this process is effective, it is fairly expensive (costing approximately $2,500 per treatment6) and
inconvenient for patients, who must be treated either weekly
or every other week and often spend the entire day in the
hospital. 3
Mipomersen (Kynamro®)
Mipomersen is a Genzyme Corporation orphan drug that has
just recently been approved by the FDA in January 2013. Mipomersen is formulated as a subcutaneous injection that is
indicated as an additional therapy option to supplement
other lipid-lowering medications and diet in adults with
HoFH. The clinical ramifications of mipomersen include reductions in low density lipoprotein-cholesterol (LDL-C),
apoB, total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C). These clinical results are attributed to mipomersen's antisense oligonucleotide inhibitor
property that prevents translation of the mRNA strand that
codes for apoB-100, the primary apolipoprotein in LDL and
vLDL. 7
In the FDA approval process, the efficacy of mipomersen was
assessed primarily using one phase III clinical trial conducted by Raal et al.B The focus of this particular study is explained, as it was the only mipomersen phase III clinical trial
specific to patients with HoFH. The other phase III clinical
trials involved patients with a high risk for CVD, which included heterozygous familial hypercholesterolemia. 9 The
Raal et al. study was a randomized, double-blind, placebocontrolled trial conducted in nine different lipid clinics in
seven different countries for 26 weeks. The inclusion factors
for patients were an age above 12 years and evidence that
pointed to HoFH in the patient. This evidence included either
genetic confirmation of HoFH, severe LDL-C concentrations
from an early age or presence of heterozygous familial hypercholesterolemia in both parents of the patient. AdditionFebruary 2014 Volume 5, Issue 1
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ally, the patients met the criteria of a consistent low-fat diet
and maximum lipid-lowering medications that were continued throughout the trial. All but one patient were taking cholesterol-lowering medications. More specifically, 76 percent were
taking a statin and an additional lipid-lowering medication. s
Out of patients screened, 51 patients met the inclusion criteria and were randomized in a 2:1 ratio in favor of the experimental group. Patients in the experimental group received
200 mg (160 mg if patient weighed <SO kg) mipomersen by
subcutaneous injection once weekly.a
The primary outcome measure was to assess efficacy by the
percent change of the LDL concentration from baseline. Secondary outcomes measured percent change from baseline for
apoB, TC, and non-HDL-C concentrations. Of the 51 patients
who entered the study, 45 completed the entire clinical trial.
The patients who discontinued treatment did so because of
adverse events, noncompliance or consent withdrawal. The
results of the Raal et al. study yielded a mean percent change
in LDL-C of -24.7 percent in the mipomersen group and
-3.3 percent in the placebo group (p=0.0003). The results for
the secondary outcomes included a mean percent change
from baseline for apoB of -26.8 percent in the mipomersen
group compared to -2.S percent in the placebo group
(p=0.0001), a TC change of -21.2 percent mipomersen compared to -2.0 percent placebo (p=0.0002), and a non-HDL-C
change of -24.S percent compared to -2.9 percent (p=.0002)
for mipomersen and placebo, respectively.a
The safety assessment of mipomersen included the Raal et al.
study in a review of four phase III clinical trials in the FDA
summary review. The Raal et al. study was specific to HoFH,
but the other phase III trials involved patients with a high
risk for CVD, which included heterozygous familial hyperchoIesterolemia. Altogether, the trials included a total of 390
patients randomized in a 2:1 ratio in the mipomersen and
placebo groups respectively for six months.9
Using the pooled data of the phase III trials, the main safety
issues were hepatic steatosis (fatty liver), injection site reactions, elevated serum transaminases, flu-like symptoms, immune/antibody responses and proteinuria.9 The Raal et al.
study, specific to HoFH, reported hepatic steatosis, elevated
transaminases, injection site reactions and flu-like symptoms, but also mentioned nausea and headache.a
In the Raal et al. study, hepatic steatosis was measured by
magnetic resonance imaging (MRI) only when a patient's
aminotransferase levels reached three times their upper
limit of normal (ULN). Consequently, four patients had an
MRI performed, which resulted in one case of an increase in
hepatic fat. Because of the few hepatic fat assessments, there
is a chance that other patients experienced undetected hepatic steatosis.s This possibility is affirmed by two other
phase III clinical trials, conducted by Stein et al. and Thomas
et al., in which the researchers conducted an MRI at baseline
and week 2s.10.11 The pooled results for these two studies
showed 62 percent of the mipomersen group versus 8 percent of the placebo group had hepatic fat increases of;::: 5 per-
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cent, the study's numerical definition of hepatic steatosis.9
Despite higher amounts of MRis utilized in these two phase
Ill trials, not all the patients were tested. For instance, in the
Stein et al. study, only 70 percent of patients had MRis completed. The other 30 percent were not measured for hepatic
steatosis because of technical difficulties, timing, metal implants or claustrophobia.10 Almost the exact same statistics
for MRls conducted were found for the Thomas et al. study
for the same reasons.11
When considering all the pooled data, the most common adverse events were injection site reactions, flu-like symptoms,
nausea, headache and elevated alanine transaminase (ALT)
and aspartate aminotransferase (AST) . These adverse events
were assessed by an incidence >10 percent and higher than
placebo.9
In the Raal et al. study, the injection site reaction was determined to be the most common adverse reaction, which
turned out to be three times more likely in the mipomersen
group. This adverse event usually manifested itself through
mild erythema, but was sometimes accompanied by local
pain, tenderness and swelling. These effects caused two patients to withdraw themselves from the trial.a When all the
phase III clinical trials of mipomersen were pooled together,
5 percent of patients were forced to discontinue therapy because of injection site reactions.9
Flu-like symptoms were observed in nearly the same percentage of patients in both groups in the Raal et al. study, but
more events per patient were noted for the mipomersen
group.a In contrast, the pooled data revealed symptoms in 30
percent of the mipomersen group and 16 percent in the placebo.9
A marked difference in ALT and AST elevations between
groups was noted in the Raal et al. study. An ALT value ~
three times the ULN was observed in 12 percent of the mipomersen group compared to zero in the placebo group.
However, no other irregular values in liver tests were observed. Only one patient discontinued treatment due to elevated ALT.B Similar results were found in the pooled studies
with 16 percent in the mipomersen versus 1 percent in the
placebo.9
Antibody response was an adverse event not measured in
the Raal et al. study, but observed in the other phase III trials
and an open-label extension study. Compiled data showed
mipomersen to be very immunogenic. The percentage of mipomersen patients who developed antibodies to mipomersen
increased from 4 percent in week 13 to 33 percent in week
50 of treatment. Proteinuria was also observed in 0.8 percent
of the placebo group and 2.3 percent of the mipomersen
group. According to the FDA summary review, clinical significance of this adverse event has yet to be determined. 9
Based upon the safety and efficacy studies noted earlier, mipomersen should be taken 200 mg subcutaneously once a
week.B.9 Patients should also be informed that each weekly
dose is priced at $4,860.4612 and that the most common side
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effect is injection site reactions.s.9
There are several factors that need to be considered before a
patient undergoes mipomersen treatment. First, as stated
previously, mipomersen is indicated specifically for adults
with HoFH. Studies have yet to be conducted with a sufficient
number of pediatric or geriatric patients to assess safety.
Additionally, patients should undergo a full liver panel inclusive of ALT, AST, total bilirubin and alkaline phosphatase
before starting mipomersen. Liver panels should be repeated
every month for the first year of treatment. After the first
year, tests should be conducted at a minimum of every three
months.7 Careful monitoring of liver panels is necessary due
to the increases in aminotransferases in some mipomersen
patients, as noted previously.9 Consequently, contraindications exist with moderate to severe hepatic impairment and
active liver disease. Furthermore, due to the risk of hepatotoxicity, the Risk Evaluation and Mitigation Strategy (REMS)
program restricts those who can prescribe and dispense mipomersen. Thus, prescribing doctors and dispensing pharmacists must be certified in the REMS program.7
The REMS program includes a prescriber training module
intended to provide education about appropriate and safe
prescribing practices. Each pharmacy wishing to dispense
the medication must also obtain certification and implement
strategies to ensure that the prescriber is certified in the
REMS program and that the patient has the necessary prescription authorization form. 20 The overarching goals of the
REMS program are the education of prescribers to ensure
safe medication utilization and the limitation of therapy to
those with a confirmed diagnosis of HoFH.
Lomitapide (Juxtapid®)
Lomitapide (Juxtapid®), an oral alternative to mipomersen
(Kynamro®), is Aegerion Pharmaceutical, lnc.'s FDAapproved orphan drug serving as an adjunct treatment for
HoFH. Approved in December 2012, it is indicated exclusively as an oral lipid-lowering therapy in patients diagnosed
with HoFH. When supplemented with a low-fat diet, LDLapheresis, and other lipid-lowering therapies, lomitapide has
demonstrated reduction in LDL-C, total cholesterol, apoB,
and non-HDL-C. 1 3 Its mechanism entails the small-molecule
inhibition of the microsomal triglyceride protein (MTP). This
enteric and hepatic endoplasmic reticular protein is responsible for the transfer of lipids to apoB to form a complex. Microsomal triglyceride protein inhibition ultimately precludes
the synthesis and secretion ofvLDL cholesterol and chylomicrons, which require apoB for assembly and subsequent
function.13 Patients can expect a clinically significant reduction in serum LDL cholesterol when combining lomitapide
therapy with both a low-fat diet and lipid-lowering therapy,
as demonstrated by the clinical trials utilized for FDA approval in the subsequent discussion.
The phase II clinical trial conducted to assess the safety, tolerability and efficacy of the novel MTP inhibitor was published in the New England Journal of Medicine in 2007.14 This
interventional, open-label, single-group assessment of lomitapide treatment in patients with HoFH was sponsored by
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Aegerion.1s Owing to the low incidence of the disease, six
patients (three men and three women, ranging 18 to 40
years of age) comprised the study group, which was conducted at a single medical facility. 14 A diet of less than 10 percent of daily caloric intake from fat was initiated for each
patient, and any other lipid-lowering therapies were held
during the course of the study. Investigators initiated dosing
at 0.03 mg/kg/day for four weeks with a successive titration
to 0.1 mg/kg/day, 0.3 mg/kg/day, and 1.0 mg/mg/day every
four weeks over the course of the 16-week study period.14
Percent reduction in LDL cholesterol was chosen as the primary outcome, followed by a number of secondary considerations including the change from baseline in triglycerides,
apoB, ALT, AST, total bilirubin, vitamins A, E and D, among
others. 14 Statistical analysis was performed using paired
t-tests or the Wilcoxon signed-rank test for continuous variables and the chi-squared test for percentages. 14 Clinically
significant reductions (p<0.001) were seen in LDL cholesterol levels, as well as both apoB and triglycerides. After four
weeks of the 0.03 mg/kg/day dose, LDL decreased 24.7 percent from a baseline of 614 mg/dL. An additional four weeks
of therapy with a 1.0 mg/kg/day dose demonstrated a total
reduction from baseline of 50.9 percent. Triglycerides saw a
decrease of 34.1 percent from baseline after four weeks of
0.03 mg/kg/day, with a total reduction of 65.2 percent after
an additional four weeks of therapy with 1.0 mg/kg/day.
After a similar dosing regimen, apoB levels were diminished
55.6 percent from baseline.14
During the course of the study, patients experienced both an
elevation in liver transaminases and accumulation of liver
fat.14 This hepatic lipid accumulation is hypothesized to be a
direct result of the mechanism and initiates potential
progression to fibrotic liver disease. Although additional
long-term studies are indicated to further assess these implications, patients should be monitored for increases in aminotransferase levels and hepatic steatosis during therapy.
This study further suggests that the adverse hepatic effects
may impair the clinical utility of lomitapide.
The phase III clinical assessment of the safety and efficacy of
lomitapide was verified by the FDA in January 2013.16 It was
also an interventional, open-label, intention to treat, singlegroup assessment conducted in 29 patients at 11 medical
facilities. For six weeks prior to initiation of lomitapide therapy, patients entered a 'run-in' phase, during which current
lipid-lowering therapies were stabilized and a low-fat diet
(less than 20 percent) was initiated. Dosing was titrated from
an initial oral dose of 5 mg/day for two weeks to an eventual
60 mg/day at four-week intervals.
Percentage reduction in LDL cholesterol was again pronounced as the primary outcome and was assessed through
week 26 of therapy. Secondary outcomes were very similar
to phase II and included percent change from baseline in total cholesterol, apoB, triglycerides, HDL, AST, ALT, and numerous others. In the 29 patients evaluated, a 40.1 ± 31.25
percent reduction was observed in LDL cholesterol levels.
Reductions from baseline in total cholesterol, apoB, and
February 2014 Volume 5, Issue 1
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triglycerides were 36.4 ± 28.2 percent, 39.4 ± 30.01 percent,
and 29.0 ± 55.72 percent, respectively.16 Both the primary
and secondary outcomes lack statistical analysis due to the
trial information not yet having reached publication.
Six of the 29 initial participants failed to complete the study,
and four of these discontinuations are attributed to adverse
events. Both serious and more common adverse events associated with lomitapide therapy have been observed from the
first dose until 28 days post-treatment. Rare yet serious adverse events included cardiac disorders (angina pectoris:
chest pain secondary to ischemic cardiac muscle, coronary
artery atherosclerosis: plaque accumulation in the coronary
artery and acute coronary syndrome: an emergent situation
in which blood supply to heart muscle is interrupted), lower
respiratory tract infections and menorrhagia.16 More notable
common adverse events, at least one of which affected 23 of
the 29 participants, included gastrointestinal disorders, pain,
fatigue, pyrexia, increased infection incidence and diverse
pain complaints. Elevations in ALT, AST and transaminases
are also under investigation for a potential patient safety
risk.
After analysis of available lomitapide safety information, the
primary concern during the course of therapy is the risk of
hepatotoxicity. This is manifested through an increase in
both AST and ALT ::?: three times the ULN. Hepatic fat increases were also noted, augmenting a patient's risk of developing steatohepatitis and cirrhosis.17 Therapy should be discontinued if a patient experiences transaminase elevations
concomitantly with clinical symptoms of liver injury. Elevations resolve within one to four weeks of stopping therapy in
most patients.18
Lomitapide therapy is contraindicated in moderate to severe
hepatic impairment, active liver disease, pregnancy and concurrent therapy with moderate or strong CYP3A4 inhibitors,
such as clarithromycin, ritonavir and telithromycin.19 A number of dose adjustments should also be considered where
applicable. Dose-related myopathy has been noted with concomitant use of simvastatin (also suspected with lovastatin),
and a reduction of the simvastatin dose by 50 percent is recommended upon lomitapide initiation.19 A maximum daily
dose of 40 mg is recommended in patients with end stage
renal disease (ESRD) or mild hepatic impairment (Child
Pugh A).18
The target population for lomitapide therapy includes those
with a clinical or laboratory diagnosis of HoFH, excluding
those with routine dyslipidemia. The study was a once daily
oral therapy available in 5 mg, 10 mg and 20 mg capsules
with an average cost per a 28 capsule bottle of $27,156.
Therapy is initiated at 5 mg once daily and increased to a 10
mg daily dose after two weeks of patient tolerance. The dose
may then be increased to 20 mg, 40 mg and a maximum of 60
mg at four-week intervals for peak therapeutic efficacy.18
Each capsule should be swallowed whole with a glass of water two hours following the evening meal.

THE PHARMACY AND WELLNESS REVIEW

5

A Comparison ofMipomersen (Kynamro®) and Lomitapide (Juxtapid®) ...

Cardiology

Table 1. Clinical Comparison of Mipomersen and Lomitapide?,12
Basis of Comparison

Mipomersen
(Kynamro®)

Lomitapide
(Juxtapid®)

Cost

$4,860.46 per weekly dose

$27,156.00 per 28 capsules

Route and Frequency
of Administration

subQ, Qweek

oral, QD

Side Effects

Injection site reactions, flu-like symptoms,
nausea, headache and elevated
transaminases

GI upset, blood and lymphatic disorders,
cardiac palpitations, chest pain, fatigue,
pyrexia, headache, dizziness, weight loss
and diverse musculoskeletal pain

Adverse Effects

Hepatotoxicity, hepatic steatosis, elevated
ALT and AST, immunogenicity
and proteinuria

Hepatotoxicity, cardiac disorders, lower
respiratory tract infections and
reproductive system disorders

Monitoring

Baseline: ALT, AST, total bilirubin and
alkaline phosphatase
Test liver transaminases levels monthly
for the first year and subsequently every
three months.
Also test before dosage increases.

Baseline: ALT, AST, total bilirubin, alkaline phosphatase, and pregnancy testing
Test liver transaminases levels monthly
for the first year and subsequently every
three months.
Also test before dosage increases.

Contraindications

Moderate to severe hepatic impairment
and active liver disease

Moderate to severe hepatic impairment,
active liver disease, pregnancy and
concurrent therapy with moderate or
strong CYP3A4 inhibitors

Additional Considerations

Prescriber and pharmacy
require REMS certification

Prescriber and pharmacy
require REMS certification

Pharmacists need to be cognizant of both common and serious adverse events that may impact patients during the
course of therapy. During the escalation of treatment doses
in the safety and efficacy trial, 10.34 percent of patients experienced a serious adverse event that included cardiac disorders, lower respiratory tract infections and reproductive
system disorders. More commonly, patients were at risk for a
number of mild adverse effects. Gastrointestinal upset, blood
and lymphatic disorders, cardiac palpitations, chest pain,
fatigue, pyrexia, headache, dizziness, weight loss and diverse
musculoskeletal pain are among the most notable.16
Additional counseling points may be appropriate for certain
patient populations. Because lomitapide is formulated with
lactose, diarrhea and intestinal malabsorption may be experienced in patients with hereditary galactose intolerance,
Lapp lactase deficiency or glucose-galactose malabsorption.
It would be appropriate to suggest supplementation with fatsoluble vitamins to all patients due to decreased absorption.ls
Upon initiation of therapy, baseline AST, ALT, total bilirubin,
alkaline phosphatase and pregnancy testing in females of
reproductive age should be recommended. Liver transami-

6

nases should subsequently be measured monthly during the
first year, every three months thereafter and prior to any
increase in dose.rn
Due to the specificity of its indication, risk of hepatotoxicity
and continuous monitoring associated with therapy, lomitapide may only be prescribed and dispensed by health care
professionals and pharmacies that are certified in the REMS
program.20
Conclusion
As an orphan disease, HoFH has long been treated using the
standardized treatments indicated for hyperlipidemia, despite its greatly increased severity and treatment challenges.
With the approval of mipomersen and lomitapide as more
targeted and specialized treatments for HoFH, patients can
experience greater convenience in taking an oral medication
or administering a subcutaneous injection than they would
experience with LDL-apheresis, an expensive and timeconsuming procedure that has long been the best treatment
option. These orphan drugs have been shown to improve
serum cholesterol levels and may promote favorable clinical
outcomes for patients with HoFH.
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A Comparison ofMipomersen (Kynamro®) and Lomitapide (Juxtapid®) ...

Assessment Questions
1.

Mild adverse events associated with administration of
lomitapide include all of the following EXCEPT:
A. Blood and lymphatic disorders
B. Chest pain
C. GI upset
D. Hyperkalemia

2.

Which of the following are appropriate baseline
monitoring parameters for a patient initiating lomitapide
therapy?
A. AST/ALT
B. Total bilirubin
C. Pregnancy testing
D. Two of the above
E. All of the above

3.

In which of the following patient populations is
lomitapide therapy most appropriately indicated?
A. Monotherapy in patients diagnosed with HoFH
B. Lipid-lowering therapy in patients with
hyperlipidemia unresponsive to statin therapy
C. As an adjunct to low-fat diet and lipid-lowering
therapy in patients with HoFH diagnosis
D. Monotherapy in patients diagnosed with
heterozygous familial hypercholesterolemia

4.

Health care professionals and pharmacists must be enrolled in the Risk Evaluation and Mitigation Strategy
(REMS) program for which of the following reasons?
A. Risk ofhepatotoxicity
B. Specificity of indication
C. Need for continuous monitoring
D. All of the above

5.

What is the most common side effect associated with
mipomersen treatment?
A. Flu-like symptoms
B. Nausea
C. Injection site reactions
D. Headache

6.

7.

Baseline monitoring for mipomersen is the same as
lomitapide EXCEPT for:
A. ALT/AST
B. Pregnancy testing
C. Total bilirubin
D. Alkaline phosphatase
What is the mechanism of action associated with
mipomersen?
A. Small-molecule inhibition of microsomal
triglyceride protein (MTP)
B. Antisense oligonucleotide inhibitor
C. HMG-CoA reductase inhibitor
D. NPC1L1 antagonist

8.

After initiation of mipomersen or lomitapide treatment,
how frequently should a patient have ALT/ AST tests
conducted?
A. Every six months
B. Every month for the first year, then discontinue
tests
C. Every month during the course of treatment
D. Every month for the first year, then every
three months

9.

Which of the following are characteristic symptoms of
HoFH?
A. Xanthomas
B. Total serum cholesterol of greater than
1,300 mg/dL
C. Early-onset cardiovascular diseases, including
coronary artery disease, angina of effort, aortic
stenosis and myocardial infarction
D. A and C only
E. All of the above

10. Which of the following conventional treatments
(nonspecific for HoFH) can be used in the treatment of
HoFH?
A. Lifestyle modifications including low-fat,
low-cholesterol diet, weight control, moderation
of alcohol intake and smoking cessation
B. Pharmacological therapy including statins,
resins (also known as bile acid sequestrants),
fibrates, nicotinic acid (also known as niacin)
and cholesterol absorption inhibitors
C. LDL-apheresis
D. A and 8 only
E. All of the above
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The program objectives were clear.
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Describe the clinical symptoms of homozygous familial hypercholesterolemia (HoFH).
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Identify conventional and adjunct treatments used for HoFH before
the development and FDA approval ofmipomersen and lomitapide.
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Identify the mechanism of action for both mipomersen and lomitapide.
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5

Identify mipomersen and lomitapide's place in therapy in the treatment
ofHoFH.
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5

Discuss the common adverse events and appropriate monitoring
parameters associated with mipomersen and lomitapide therapy.
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The program met your educational needs.
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Content of the program was interesting.
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Material presented was relevant to my practice.
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The program met the stated goals and objectives:

Comments/Suggestions for future programs:
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Answers to Assessment Questions-Please Circle Your Answer
1.

A B C D

4.

A B C D

7.

A B C D

2.

A B C D E

5.

A B C D

8.

A B C D

3.

A B C D

6.

ABCD

9.

A B C D E

10. A B C D E
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